Table 1.
Baseline characteristics of patients with IgA nephropathy.
Table 2.
Follow-up data and clinical outcomes of patients with IgA nephropathy.
Table 3.
Comparison of clinical parameters at renal biopsy against MEST-C scores.
Fig 1.
Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD.
(a) Kaplan-Meier curves showing survival from combined event in the entire cohort, categorized by, (b) presence of hypertension at clinical presentation (c) degree of TA-proteinuria, (d) tubular atrophy/interstitial fibrosis (T) score (e) cellular/fibrocellular crescent (C) score and (f) nephrotic range proteinuria (NRP) with sub-nephrotic range proteinuria at biopsy.
Fig 2.
Secondary endpoint analysis, i.e., time to development of ESRD.
Kaplan-Meier curve showing the survival from ESRD in the entire cohort.
Table 4.
Correlations between clinical, laboratory and pathology with renal outcomes.
Table 5.
Clinical, laboratory and histological characteristics of patients with IgA nephropathy presenting with nephrotic range proteinuria and sub-nephrotic proteinuria.